Clinical Trials
5 trialsNCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT03895112 2023-02-10
MPN-RC 118 AVID200 in Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02151864 2019-03-05
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
University of California, San Diego
Phase 1 Completed
NCT00706576 2017-08-02
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
University of Missouri-Columbia
Phase 1 Completed
NCT00802555 2012-07-12
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed